fashion -WSS

fashion

author：comprehensive 2025-09-05 18:45:36 - browse：7

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How housing is health care on Long Island

focus

WSS

United colonoscopy coverage change 'may cost lives,' doctors say

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medical records are filled with copy

White House touts steps to stem shortages of cancer treatments

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

focus

fashion

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Hospitals consider fixing cancer drug shortages on their own

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WATCH: Why do bright lights make us see spots?

New air purifier tech could be key to improving indoor air quality

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Activists slam private health insurers over coverage restrictions

FDA proposes changes to key medical devices approval pathway

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Drug repurposing or repositioning? The language matters

Walensky prepares to leave CDC — and Congress — behind

Sports medicine is finally prioritizing gender equality

How to make the FDA’s new prescription one

FDA proposes changes to key medical devices approval pathway

leisure time

focus

explore

hotspot